GlassScriptPhysician profile
Benedict O Ifedi
NPI 1134531445
$4,207.33
in general payments reported to CMS, 2019-2025
23 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $215 · 2021: $341 · 2022: $623 · 2023: $512 · 2024: $795 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $954.97 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $722.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $514.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $346.24 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pacira Therapeutics, INC. | $258.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $237.51 | 2019 | |
| Pfizer INC. | $143.90 | 2022-2025 | |
| Exact Sciences Corporation | $134.09 | 2023-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $120.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $118.98 | 2023 | Seglentis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2020 | |
| Currax Pharmaceuticals LLC | $87.00 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Dexcom, INC. | $80.41 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $75.48 | 2019 | |
| Merck Sharp & Dohme LLC | $69.33 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.90 | 2022-2023 | Synjardy, Jardiance |
| Hologic Sales and Service, LLC | $40.92 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.87 | 2022 | |
| Bioventus LLC | $34.20 | 2019 | |
| Glaxosmithkline, LLC. | $34.03 | 2019-2024 | Arexvy, Shingrix |
| Genentech USA, INC. | $15.06 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.28 | 2024 | Quviviq |
| Amgen INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Ifedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.